Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Favrille has completed enrollment in a pivotal phase III clinical trial designed to evaluate its drug FavId following Rituxan therapy for the treatment of follicular B-cell non-Hodgkin's lymphoma.
Subscribe to our email newsletter
The randomized, double-blind, placebo-controlled trial has been conducted at 67 oncology centers across the U.S. The trial has enrolled both treatment-naive and relapsed/refractory patients with stable or responding disease following treatment with Rituxan.
“The rapid enrollment supports our belief that an all-biologic regimen of Rituxan followed by FavId could, if approved, become the option preferred by patients with indolent B-cell NHL who wish to avoid many of the side effects associated with chemotherapy,” said Dr John Bender, senior vice-president of Clinical Research.
In addition, the FDA has granted fast track designation for the drug indicating that the FDA will expedite the review of the drug.
Favrille is a biopharmaceutical company developing patient-specific immunotherapies for the treatment of cancer.